Phathom Pharmaceuticals Completes Enrollment for Voquezna Clinical Trial
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 23 2026
0mins
Phathom Pharmaceuticals announced it has completed enrollment in its Phase 2 pHalcon-EoE-201 clinical trial evaluating Voquezna tablets as an investigational treatment for eosinophilic esophagitis in adults. The study has enrolled 95 patients at 41 U.S. sites. Topline results are anticipated in the fourth quarter 2026.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PHAT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PHAT
Wall Street analysts forecast PHAT stock price to rise
6 Analyst Rating
5 Buy
1 Hold
0 Sell
Strong Buy
Current: 11.200
Low
16.00
Averages
25.40
High
29.00
Current: 11.200
Low
16.00
Averages
25.40
High
29.00
About PHAT
Phathom Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the commercialization and development of novel treatments for gastrointestinal diseases. It has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB) for the United States (U.S.), Europe and Canada. PCABs are a novel class of molecules that block acid secretion in the stomach. The Company markets vonoprazan in the U.S. as VOQUEZNA (vonoprazan) tablets for the relief of heartburn associated with non-erosive gastroesophageal reflux disease (Non-Erosive GERD) in adults, the healing and maintenance of healing of Erosive GERD in adults and relief of associated heartburn, and as part of VOQUEZNA DUAL PAK (vonoprazan tablets, amoxicillin capsules) and VOQUEZNA TRIPLE PAK (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) for the treatment of H. pylori infection in adults.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Phathom Pharmaceuticals Completes Enrollment in EoE Clinical Trial
- Trial Enrollment Completed: Phathom Pharmaceuticals announced the completion of enrollment for its Phase 2 pHalcon-EoE-201 clinical trial evaluating VOQUEZNA (vonoprazan) for Eosinophilic Esophagitis, marking a significant advancement in gastrointestinal disease treatment.
- Study Design Details: The trial is a two-part, randomized, double-blind, placebo-controlled study, with 95 adults receiving either VOQUEZNA 20 mg or placebo daily for 12 weeks in Part 1, aimed at assessing the drug's efficacy and safety.
- Future Development Expectations: Should the Phase 2 trial yield positive results, Phathom plans to discuss future development plans for EoE with the FDA, including evaluations for pediatric patients, potentially opening new market opportunities.
- Stock Performance: PHAT has traded between $7.61 and $18.31 over the past year, currently up 0.94% at $10.78, reflecting positive market sentiment regarding its clinical progress.
See More
Phathom Pharmaceuticals to Attend Upcoming Investor Conferences
- Investor Conference Schedule: Phathom Pharmaceuticals is set to participate in several investor conferences in May and June 2026, including the Craig-Hallum Annual Conference on May 28, where management will engage in one-on-one meetings to enhance investor relations.
- Key Conference Dates: The company will also attend the Jefferies Global Healthcare Conference on June 3 and the Goldman Sachs Global Healthcare Conference on June 9, with management participating in fireside chats to showcase the company's strategic direction and market potential.
- Webcast Access: Live webcasts and recordings of all events will be available on Phathom's website under the News & Events section, with recordings accessible for 90 days post-event, ensuring investors can obtain critical information at their convenience.
- Product Commercialization Progress: Phathom focuses on developing and commercializing novel treatments for gastrointestinal diseases, particularly its first-in-class drug vonoprazan, which has been launched in the U.S. market, demonstrating the company's innovative capabilities and competitive edge in the healthcare sector.
See More
Phathom Pharmaceuticals to Announce Q1 Earnings on April 30
- Earnings Announcement: Phathom Pharmaceuticals is set to release its Q1 earnings report on April 30 before market open, with a consensus EPS estimate of -$0.19, reflecting an 82.2% year-over-year improvement, indicating potential for enhanced profitability.
- Strong Revenue Expectations: The anticipated revenue for Q1 is $56.81 million, representing a 99.3% year-over-year increase, which suggests significant growth in market demand and product sales, likely to positively impact stock performance.
- Historical Performance Review: Over the past year, Phathom has beaten EPS and revenue estimates 75% of the time, showcasing reliability in market analysis and performance forecasting, which boosts investor confidence.
- Future Outlook: The company has set a revenue guidance target of $320 million to $345 million for 2026, aiming for operational profitability, reflecting its confidence and strategic planning for future growth.
See More
Barclays Upgrades Phathom to Overweight Amid Sales Recovery Prospects
- Rating Upgrade: Barclays upgraded Phathom Pharmaceuticals (PHAT) from equal weight to overweight, reflecting confidence in the anticipated sales recovery of its heartburn drug Voquezna, with significant growth expected in Q2.
- Price Target Adjustment: The bank raised its price target for Phathom from $16 to $18, indicating approximately 67% upside based on the March 26 close, showcasing a positive outlook on the company's future performance.
- Improving Sales Trends: Despite a ~36% year-to-date decline in Phathom's stock price, analysts noted positive sales trends in March, particularly with prescriptions peaking on March 13, surpassing levels seen in Q4 2025, indicating a rebound in market demand.
- Strategic Commercial Focus: Phathom's targeted approach towards gastrointestinal providers rather than a broader GI and primary care focus may serve as a tailwind for increased adoption of Voquezna, suggesting that this strategic positioning could enhance market penetration.
See More
PHATHOM PHARMACEUTICALS INC.: BARCLAYS INCREASES TARGET PRICE FROM $16 TO $18
- Analyst Update: Barclays has raised the price target for Phathom Pharmaceuticals from $16 to $18.
- Market Implications: This adjustment reflects a positive outlook on the company's performance and potential growth in the pharmaceutical sector.
See More
Surge in Options Trading Volume for Adobe and Phathom Pharmaceuticals
- Adobe Options Volume: Adobe Inc saw options trading volume of 58,412 contracts, equivalent to approximately 5.8 million shares, representing about 88.3% of its average daily trading volume of 6.6 million shares over the past month, indicating strong market interest in its future performance.
- High Put Option Activity: Notably, the $290 strike put option has seen 5,001 contracts traded today, representing around 500,100 shares of Adobe, reflecting investor expectations for potential price declines.
- Phathom Options Activity: Phathom Pharmaceuticals Inc recorded an options trading volume of 10,012 contracts, equivalent to approximately 1.0 million shares, which is about 86.9% of its average daily trading volume of 1.2 million shares over the past month, showcasing significant market interest.
- Call Option Trading: For Phathom, the $7.50 strike call option has also seen a trading volume of 5,001 contracts today, representing approximately 500,100 shares, indicating investor confidence in the company's future price appreciation.
See More
Phathom Pharmaceuticals Completes Enrollment in EoE Clinical Trial
- Trial Enrollment Completed: Phathom Pharmaceuticals announced the completion of enrollment for its Phase 2 pHalcon-EoE-201 clinical trial evaluating VOQUEZNA (vonoprazan) for Eosinophilic Esophagitis, marking a significant advancement in gastrointestinal disease treatment.
- Study Design Details: The trial is a two-part, randomized, double-blind, placebo-controlled study, with 95 adults receiving either VOQUEZNA 20 mg or placebo daily for 12 weeks in Part 1, aimed at assessing the drug's efficacy and safety.
- Future Development Expectations: Should the Phase 2 trial yield positive results, Phathom plans to discuss future development plans for EoE with the FDA, including evaluations for pediatric patients, potentially opening new market opportunities.
- Stock Performance: PHAT has traded between $7.61 and $18.31 over the past year, currently up 0.94% at $10.78, reflecting positive market sentiment regarding its clinical progress.
See More
Phathom Pharmaceuticals to Attend Upcoming Investor Conferences
- Investor Conference Schedule: Phathom Pharmaceuticals is set to participate in several investor conferences in May and June 2026, including the Craig-Hallum Annual Conference on May 28, where management will engage in one-on-one meetings to enhance investor relations.
- Key Conference Dates: The company will also attend the Jefferies Global Healthcare Conference on June 3 and the Goldman Sachs Global Healthcare Conference on June 9, with management participating in fireside chats to showcase the company's strategic direction and market potential.
- Webcast Access: Live webcasts and recordings of all events will be available on Phathom's website under the News & Events section, with recordings accessible for 90 days post-event, ensuring investors can obtain critical information at their convenience.
- Product Commercialization Progress: Phathom focuses on developing and commercializing novel treatments for gastrointestinal diseases, particularly its first-in-class drug vonoprazan, which has been launched in the U.S. market, demonstrating the company's innovative capabilities and competitive edge in the healthcare sector.
See More
Phathom Pharmaceuticals to Announce Q1 Earnings on April 30
- Earnings Announcement: Phathom Pharmaceuticals is set to release its Q1 earnings report on April 30 before market open, with a consensus EPS estimate of -$0.19, reflecting an 82.2% year-over-year improvement, indicating potential for enhanced profitability.
- Strong Revenue Expectations: The anticipated revenue for Q1 is $56.81 million, representing a 99.3% year-over-year increase, which suggests significant growth in market demand and product sales, likely to positively impact stock performance.
- Historical Performance Review: Over the past year, Phathom has beaten EPS and revenue estimates 75% of the time, showcasing reliability in market analysis and performance forecasting, which boosts investor confidence.
- Future Outlook: The company has set a revenue guidance target of $320 million to $345 million for 2026, aiming for operational profitability, reflecting its confidence and strategic planning for future growth.
See More
Barclays Upgrades Phathom to Overweight Amid Sales Recovery Prospects
- Rating Upgrade: Barclays upgraded Phathom Pharmaceuticals (PHAT) from equal weight to overweight, reflecting confidence in the anticipated sales recovery of its heartburn drug Voquezna, with significant growth expected in Q2.
- Price Target Adjustment: The bank raised its price target for Phathom from $16 to $18, indicating approximately 67% upside based on the March 26 close, showcasing a positive outlook on the company's future performance.
- Improving Sales Trends: Despite a ~36% year-to-date decline in Phathom's stock price, analysts noted positive sales trends in March, particularly with prescriptions peaking on March 13, surpassing levels seen in Q4 2025, indicating a rebound in market demand.
- Strategic Commercial Focus: Phathom's targeted approach towards gastrointestinal providers rather than a broader GI and primary care focus may serve as a tailwind for increased adoption of Voquezna, suggesting that this strategic positioning could enhance market penetration.
See More
PHATHOM PHARMACEUTICALS INC.: BARCLAYS INCREASES TARGET PRICE FROM $16 TO $18
- Analyst Update: Barclays has raised the price target for Phathom Pharmaceuticals from $16 to $18.
- Market Implications: This adjustment reflects a positive outlook on the company's performance and potential growth in the pharmaceutical sector.
See More
Surge in Options Trading Volume for Adobe and Phathom Pharmaceuticals
- Adobe Options Volume: Adobe Inc saw options trading volume of 58,412 contracts, equivalent to approximately 5.8 million shares, representing about 88.3% of its average daily trading volume of 6.6 million shares over the past month, indicating strong market interest in its future performance.
- High Put Option Activity: Notably, the $290 strike put option has seen 5,001 contracts traded today, representing around 500,100 shares of Adobe, reflecting investor expectations for potential price declines.
- Phathom Options Activity: Phathom Pharmaceuticals Inc recorded an options trading volume of 10,012 contracts, equivalent to approximately 1.0 million shares, which is about 86.9% of its average daily trading volume of 1.2 million shares over the past month, showcasing significant market interest.
- Call Option Trading: For Phathom, the $7.50 strike call option has also seen a trading volume of 5,001 contracts today, representing approximately 500,100 shares, indicating investor confidence in the company's future price appreciation.
See More
